Evonik Industries (FRA:EVK) has been assigned a €27.50 ($31.98) target price by investment analysts at HSBC in a research report issued on Wednesday. The brokerage presently has a “neutral” rating on the stock. HSBC’s price target would suggest a potential upside of 6.59% from the company’s previous close.
Several other research analysts also recently commented on EVK. Berenberg Bank set a €30.00 ($34.88) target price on Evonik Industries and gave the stock a “buy” rating in a research note on Thursday, March 7th. JPMorgan Chase & Co. set a €26.00 ($30.23) target price on Evonik Industries and gave the stock a “neutral” rating in a research note on Tuesday. UBS Group set a €23.00 ($26.74) target price on Evonik Industries and gave the stock a “sell” rating in a research note on Tuesday. Warburg Research set a €35.75 ($41.57) target price on Evonik Industries and gave the stock a “buy” rating in a research note on Thursday, March 7th. Finally, Sanford C. Bernstein set a €30.00 ($34.88) target price on Evonik Industries and gave the stock a “buy” rating in a research note on Tuesday, March 5th. Three analysts have rated the stock with a sell rating, eight have issued a hold rating and eleven have given a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average target price of €31.06 ($36.12).
Shares of FRA EVK opened at €25.80 ($30.00) on Wednesday. Evonik Industries has a 52 week low of €26.78 ($31.14) and a 52 week high of €32.97 ($38.34).
Evonik Industries Company Profile
Evonik Industries AG engages in the specialty chemicals business worldwide. It operates through Nutrition & Care, Resource Efficiency, Performance Materials, and Services segments. The Nutrition & Care segment offers specialty chemicals, including amphoteric surfactants, ceramides, phytosphingosines, oleochemical quaternary derivatives, polyurethane additives, organically modified silicones, superabsorbents, amino acids and amino acid derivatives, synthesis products, pharmaceutical polymers, and DL-methionine for use in consumer goods, and animal nutrition and healthcare products.
Featured Story: How a Strangle Strategy is different from a Straddle Strategy
Receive News & Ratings for Evonik Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evonik Industries and related companies with MarketBeat.com's FREE daily email newsletter.